Your browser doesn't support javascript.
loading
Deep learning enables rapid identification of potent DDR1 kinase inhibitors.
Zhavoronkov, Alex; Ivanenkov, Yan A; Aliper, Alex; Veselov, Mark S; Aladinskiy, Vladimir A; Aladinskaya, Anastasiya V; Terentiev, Victor A; Polykovskiy, Daniil A; Kuznetsov, Maksim D; Asadulaev, Arip; Volkov, Yury; Zholus, Artem; Shayakhmetov, Rim R; Zhebrak, Alexander; Minaeva, Lidiya I; Zagribelnyy, Bogdan A; Lee, Lennart H; Soll, Richard; Madge, David; Xing, Li; Guo, Tao; Aspuru-Guzik, Alán.
Afiliación
  • Zhavoronkov A; Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong. alex@insilico.com.
  • Ivanenkov YA; Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.
  • Aliper A; Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.
  • Veselov MS; Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.
  • Aladinskiy VA; Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.
  • Aladinskaya AV; Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.
  • Terentiev VA; Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.
  • Polykovskiy DA; Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.
  • Kuznetsov MD; Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.
  • Asadulaev A; Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.
  • Volkov Y; Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.
  • Zholus A; Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.
  • Shayakhmetov RR; Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.
  • Zhebrak A; Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.
  • Minaeva LI; Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.
  • Zagribelnyy BA; Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.
  • Lee LH; WuXi AppTec Co., Ltd, Shanghai, China.
  • Soll R; WuXi AppTec Co., Ltd, Shanghai, China.
  • Madge D; WuXi AppTec Co., Ltd, Shanghai, China.
  • Xing L; WuXi AppTec Co., Ltd, Shanghai, China.
  • Guo T; WuXi AppTec Co., Ltd, Shanghai, China.
  • Aspuru-Guzik A; Department of Chemistry, University of Toronto, Toronto, Ontario, Canada.
Nat Biotechnol ; 37(9): 1038-1040, 2019 09.
Article en En | MEDLINE | ID: mdl-31477924
ABSTRACT
We have developed a deep generative model, generative tensorial reinforcement learning (GENTRL), for de novo small-molecule design. GENTRL optimizes synthetic feasibility, novelty, and biological activity. We used GENTRL to discover potent inhibitors of discoidin domain receptor 1 (DDR1), a kinase target implicated in fibrosis and other diseases, in 21 days. Four compounds were active in biochemical assays, and two were validated in cell-based assays. One lead candidate was tested and demonstrated favorable pharmacokinetics in mice.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Evaluación Preclínica de Medicamentos / Receptor con Dominio Discoidina 1 / Aprendizaje Profundo Tipo de estudio: Diagnostic_studies Límite: Animals / Humans Idioma: En Revista: Nat Biotechnol Asunto de la revista: BIOTECNOLOGIA Año: 2019 Tipo del documento: Article País de afiliación: Hong Kong

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Evaluación Preclínica de Medicamentos / Receptor con Dominio Discoidina 1 / Aprendizaje Profundo Tipo de estudio: Diagnostic_studies Límite: Animals / Humans Idioma: En Revista: Nat Biotechnol Asunto de la revista: BIOTECNOLOGIA Año: 2019 Tipo del documento: Article País de afiliación: Hong Kong